Status:
UNKNOWN
Levetiracetam (Keppra) to Improve Chronic Aphasia in Post-stroke Patients.
Lead Sponsor:
Kessler Foundation
Collaborating Sponsors:
UCB Pharma
Conditions:
Aphasia
Stroke
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The study investigates the possibility that levetiracetam may improve the symptoms of chronic post-stroke aphasia.
Detailed Description
In the study, 50 post-stroke subjects with aphasia will take levetiracetam and we will evaluate their speech, language, and memory in an ABAB design.
Eligibility Criteria
Inclusion
- Stroke
- Aphasia
- Can give consent
Exclusion
- Renal failure
- Pregnancy
- Other neurological condition
Key Trial Info
Start Date :
September 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2021
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00227461
Start Date
September 1 2005
End Date
December 1 2021
Last Update
February 17 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kessler Foundation
West Orange, New Jersey, United States, 07052